Rewind only a year, and it seemed reasonable to assume that Covid-19 would transform the prospects of the major pharmaceutical multinationals.
Three safe and effective vaccines were developed in a year; regulators worked at record speed to get them approved and governments pre-bought doses in the millions to ramp up production – perhaps the same would happen for a whole range of other diseases.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
What went wrong?
True, a lot of money has been made over the last couple of years. Pfizer’s jab, the most widely used, has been a blockbuster, delivering annualised sales of $37bn, almost doubling its turnover, and turning the jab into the biggest pharmaceutical product in the world. Moderna and AstraZeneca did not make quite so much, but still chalked up nine-digit revenues for their vaccines.
And yet, despite that, there is not much sign that progress can be sustained – the share prices of many of the main players have been tumbling. True, the wider stockmarket has also been weak, especially for innovative, technology-based companies, but even so, there is no escaping the fact that Covid-19 is not turning into a catalyst for rapid growth in the industry. No one is making a fortune out of Covid-19 anymore.
There were three big issues. First, the Omicron variant was more infectious, but at least somewhat milder than the Delta variant, and it only partly evaded existing vaccines. There was almost no way of stopping it from spreading, but fortunately very few vaccinated people who caught it required hospitalisation. Sure, it was still sensible to get vaccinated, and to get a booster as well, but the demand for the jabs inevitably started to wane. Flu vaccines are a major product, but in reality most people don’t bother because they are not that worried about catching it. As 2022 unfolded, Omicron meant Covid-19 was starting to go the same way.
Next, vaccination kills its own market. It is a paradox of developing and manufacturing vaccines that, the more successful they are, the less demand there ends up being. At the most extreme level, the disease is completely wiped out so that no one needs to worry about it anymore: polio has been largely eliminated from the developed world and measles and mumps have been tamed. Some of the drug companies are pushing for annualised vaccination against Covid-19, especially for the elderly or vulnerable, but it is starting to look as if two or three jabs will be enough. Almost all of us have been vaccinated now, and that means the demand isn’t there any longer.
Too greedy for their own good
Finally, and most importantly, the firms were too greedy. The AstraZeneca Oxford vaccine was the obvious exception, sold at cost price, but Moderna and Pfizer both pushed for very high prices, charging health systems as much as $30 per jab.
That now looks to have been a critical mistake; the wealthy countries could afford it, but the vaccines were unaffordable for many others, and countries have relied on home-grown alternatives, or opted for herd immunity instead. Even worse, it fuelled demands for the companies to be stripped of patent protection. It would have been far better to charge just two or three dollars per jab and make sure the whole world was vaccinated. Instead, the companies put short-term profits over building a long-term business.
The virus might bounce back. Hong Kong is in the middle of a full-blown epidemic and there are signs it is spreading across mainland China. If China were willing to admit its own vaccines were not very effective, and ordered the Pfizer or AstraZeneca jabs instead, that would revive the market. Otherwise, the boom has fizzled out. The pharma industry may have imagined it was going to make a fortune from the virus and start a new golden era of innovation. It has not worked out that way – and the industry looks stuck with modest growth at best for a long time to come.
-
HMRC savings tax crackdown: More workers to pay tax directly from their wagesBanks and building societies will be required to obtain National Insurance numbers from savers to make it easier for HMRC to tax those who breach their personal savings allowance
-
It’s time to start backing the UK stock marketThe UK stock market has been languishing for decades. But the tide is turning and smart investors should buy in now
-
Global equities that should prove resilient to the stock market’s stormsOpinion Alex Illingworth of Goshawk Asset Management highlights three diverse opportunities in global equities despite a turbulent landscape
-
US stocks are more expensive than ever after Trump's tariffsWe don’t need to second-guess the effect of Trump's tariffs to think that the rest of the world offers better value
-
How to use SAYE and SIP schemes to multiply your moneyEmployers’ savings or share-incentive plans like SAYE and SIP schemes can help top up your pension
-
Where investors can find value nowOpinion Active fund managers and blue chips on both sides of the Atlantic look appealing, says ByteTree’s Charlie Morris
-
UK equities: where to find a great British bargainUK equities are staging a comeback, but there’s still plenty of value out there, says Rupert Hargreaves
-
Just Group has the wind behind it – should you invest?Just Group, a retirement products provider, is well placed to profit from a growing annuity market
-
Personal Assets Trust: a fund to protect your wealthPersonal Assets Trust aims to shelter its shareholders’ assets from volatile markets
-
Britain’s fallen stars: a second chance for quality stocksQuality stocks in the UK saw share prices collapse in the wake of Covid. That has created an opportunity for smart public investors — and private buyers
